2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1543

Traditional Risk Score Underestimates the Cardiovascular Risk in Rheumatoid Arthritis Patients
Abstract Number: 1544

Resiliency As a Predictor of Depressive Symptoms in Patients with Rheumatoid Arthritis
Abstract Number: 1545

Comparison of Statin Eligibility According to the Adult Treatment Panel III, ACC/AHA Blood Cholesterol Guideline and Presence of Carotid Plaque By Ultrasound in Hispanics with Rheumatoid Arthritis
Abstract Number: 1546

What Is the Impact of Smoking on the Risk of Rheumatoid Arthritis Progression: A Systematic Review of the Risk Factor Paradox
Abstract Number: 1547

Implementing an Electronic Medical Recorded-Based Clinical Decision Support Tool Did Not Improve Cardiovascular Risk Screening in Rheumatoid Arthritis Patients
Abstract Number: 1548

Comparison of 5 Cardiovascular Risk Calculators in a Hispanic Rheumatoid Arthritis Cohort
Abstract Number: 1549

Prevalence of Co-Morbidities and Evaluation of Their Monitoring in Korean Patients with RA: Comparison with the Results of an International, Cross-Sectional Study (COMORA)
Abstract Number: 1550

Flares of Disease Activity As Risk Factor for the Occurrence of Myocardial Infarction in Patients with Rheumatoid Arthritis
Abstract Number: 1551

Rheumatoid Vasculitis: A Decline in the XXI Century
Abstract Number: 1552

Illness Perceptions in Rheumatoid Arthritis: A Comparison of Canadian and Nigerian Patients
Abstract Number: 1553

Effect of Drug Therapy on Net Cholesterol Efflux Capacity of HDL-Enriched Serum in Rheumatoid Arthritis
Abstract Number: 1554

Severe Pneumonia after a 13-Prevalent Pneumonoccal Conjugate Vaccine (Prevena 13) Among Patients with Rheumatoid Arthritis
Abstract Number: 1555

Geography and the Influence of Comorbidity on the Prevalence of Depression in Patients with Rheumatoid Arthritis,a Study Across Seventeen Countries
Abstract Number: 1556

The Medication Information-Seeking Behaviors of Rheumatoid Arthritis Patients Who Are Prescribed a New DMARD
Abstract Number: 1557

The Impact of Hindfoot Deformity on Disability of Korean Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].